Heat-shock protein 90 inhibitors as antitumor agents: a survey of the literature from 2005 to 2010

Bibliography

• Workman P. Altered states: selectively drugging the Hsp90 cancer chaperone. Trends Mol Med 2004;10:47-51
   PubMed Web of Science ®Google Scholar
• Chiosis G, Vilenchik M, Kim J, Solit D. Hsp90: the vulnerable chaperone. Drug Discov Today 2004;9:881-8
   PubMed Web of Science ®Google Scholar
• Sreedhar AS, Soti C, Csermely P. Inhibition of Hsp90: a new strategy for inhibiting protein kinases. Biochim Biophys Acta 2004;1697:233-42
   PubMed Web of Science ®Google Scholar
• Zhang H, Burrows F. Targeting multiple signal transduction pathways through inhibition of Hsp90. J Mol Med 2004;82:488-99
   PubMed Web of Science ®Google Scholar
• Neckers L. Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol Med 2002;8:S55-61
   PubMed Web of Science ®Google Scholar
• Miller P, Schnur RC, Barbacci E, Binding of benzoquinoid ansamycins to p100 correlates with their ability to deplete the erbB2 gene product. Biochem Biophys Res Commun 1994;201:1313-19
   PubMed Web of Science ®Google Scholar
• An WG, Schnur RC, Neckers L, Depletion of p185erbB2, Raf-1 and mutant p53 proteins by geldanamycin derivatives correlates with antiproliferative activity. Cancer Chemother Pharmacol 1997;40:60-4
   PubMed Web of Science ®Google Scholar
• Grbovic OM, Basso AD, Sawai A, V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors. Proc Natl Acad Sci USA 2006;103:57-62
   PubMed Web of Science ®Google Scholar
• Sato S, Fujita N, Tsuruo T. Modulation of Akt kinase activity by binding to Hsp90. Proc Natl Acad Sci USA 2000;97:10832-7
   PubMed Web of Science ®Google Scholar
• Blagosklonny MV, Toretsky J, Bohen S, Mutant conformation of p53 translated in vitro or in vivo requires functional HSP90. Proc Natl Acad Sci USA 1996;93:8379-83
   PubMed Web of Science ®Google Scholar
• Grad I, Picard D. The glucocorticoid responses are shaped by molecular chaperones. Mol Cell Endocrinol 2007;275:2-12
   PubMed Web of Science ®Google Scholar
• Picard D. Chaperoning steroid hormone action. Trends Endocrinol Metab 2006;17:229-35
   PubMed Web of Science ®Google Scholar
• Kuduk SD, Harris CR, Zheng FF, Synthesis and evaluation of geldanamycin-testosterone hybrids. Bioorg Med Chem Lett 2000;10:1303-6
   PubMed Web of Science ®Google Scholar
• Kuduk SD, Zheng FF, Sepp-Lorenzino L, Synthesis and evaluation of geldanamycin-estradiol hybrids. Bioorg Med Chem Lett 1999;9:1233-8
   PubMed Web of Science ®Google Scholar
• Johnson JL, Toft DO. Binding of p23 and hsp90 during assembly with the progesterone receptor. Mol Endocrinol 1995;9:670-8
   PubMedGoogle Scholar
• Forsythe HL, Jarvis JL, Turner JW, Stable association of hsp90 and p23, but not hsp70, with active human telomerase. J Biol Chem 2001;276:15571-4
   PubMed Web of Science ®Google Scholar
• Akalin A, Elmore LW, Forsythe HL, A novel mechanism for chaperone-mediated telomerase regulation during prostate cancer progression. Cancer Res 2001;61:4791-6
   PubMed Web of Science ®Google Scholar
• Kamal A, Boehm MF, Burrows FJ. Therapeutic and diagnostic implications of Hsp90 activation. Trends Mol Med 2004;10:283-90
   PubMed Web of Science ®Google Scholar
• Mitsiades CS, Hayden PJ, Anderson KC, From the bench to the bedside: emerging new treatments in multiple myeloma. Best Pract Res Clin Haematol 2007;4:797-816
   Google Scholar
• Gallegos Ruiz MI, Floor K, Roepman P, Integration of gene dosage and gene expression in non-small cell lung cancer, identification of HSP90 as potential target. G. PLoS ONE 2008;3:e1722
   Google Scholar
• Dickey CA, Kamal A, Lundgren K, The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins. J Clin Inv 2007;117:648-58
   PubMed Web of Science ®Google Scholar
• Luo W, Dou F, Rodina A, Roles of heat-shock protein 90 in maintaining and facilitating the neurodegenerative phenotype in tauopathies. PNAS 2007;104:9511-16
   PubMed Web of Science ®Google Scholar
• Neckers L. Heat shock protein 90: the cancer chaperone. J Biosci 2007;32:517-30
   PubMed Web of Science ®Google Scholar
• Stebbins CE, Russo AA, Schneider C, Crystal structure of an Hsp90–geldanamycin complex: targeting of a protein chaperone by an antitumor agent. Cell 1997;89:239-50
   PubMed Web of Science ®Google Scholar
• Prodromou C, Roe SM, O'Brien R, Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone. Cell 1997;90:65-75
   PubMed Web of Science ®Google Scholar
• Grenert JP, Sullivan WP, Fadden P, 90 (hsp90) that binds geldanamycin is an ATP/ADP switch domain that regulates hsp90 conformation. J Biol Chem 1997;272:23843-50
   PubMed Web of Science ®Google Scholar
• Marcu MG, Chadli A, Bouhouche M, The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone. J Biol Chem 2000;275:37181-6
   PubMed Web of Science ®Google Scholar
• Soti C, Racz P, Csermerly J. A Nucleotide-dependent molecular switch controls ATP binding at the C-terminal domain of Hsp90. N-terminal nucleotide binding unmasks a C-terminal binding pocket. J Biol Chem 2002;277:7066-75
   PubMed Web of Science ®Google Scholar
• Garnier C, Lafitte D, Tsvetkov PO, Binding of ATP to heat shock protein 90: evidence for an ATP-binding site in the C-terminal domain. J Biol Chem 2002;277:12208-14
   PubMedGoogle Scholar
• Shelton SN, Shawgo ME, Matthews SVB, Ku135, a novel novobiocin-derived C-terminal inhibitor of the 90-kDa heat shock protein, exerts potent antiproliferative effects in human leukemic cells. Mol Pharm 2009;76:1314-22
   Google Scholar
• Le Bras G, Radanyi C, Peyrat J-F, New novobiocin analogues as antiproliferative agents in breast cancer cells and potential inhibitors of heat shock protein 90. J Med Chem 2007;50:6189-200
   PubMed Web of Science ®Google Scholar
• Radanyi C, Le Bras G, Messaoudi S, Synthesis and biological activity of simplified denoviose-coumarins related to novobiocin as potent inhibitors of heat-shock protein 90 (hsp90). Biorg Med Chem Lett 2008;18:2495-8
   PubMedGoogle Scholar
• Radanyi C, Le Bras G, Marsaud V, Antiproliferative and apoptotic activities of tosylcyclonovobiocic acids as potent heat shock protein 90 inhibitors in human cancer cells. Cancer Lett 2009;274:88-94
   PubMed Web of Science ®Google Scholar
• Radanyi C, Le Bras G, Bouclier C, Tosylcyclonovobiocic acids promote cleavage of the hsp90-associated cochaperone p23. Biochem Biophys Res Commun 2009;379:514-18
   PubMedGoogle Scholar
• Audisio D, Messaoudi S, Cegielkowski L, Discovery and biological activity of 6BrCaQ as an inhibitor of the Hsp90 protein folding machinery. ChemMedChem 2011;6:804-15
   PubMedGoogle Scholar
• Li Y, Zhang TS, Schwartz JD, New developments in Hsp90 inhibitors as anti-cancer therapeutics: mechanisms, clinical perspective and more potential. Drug Resist Updat 2009;12:17-27
   PubMed Web of Science ®Google Scholar
• Powers MV, Workman P. Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors. Endocr Relat Cancer 2006;13:S125-35
   PubMed Web of Science ®Google Scholar
• Hostein I, Robertson D, DiStefano F, Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis. Cancer Res 2001.61:4003-9
   Google Scholar
• Kamal A, Thao L, Sensintaffar J, A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 2003;425:407-10
   PubMed Web of Science ®Google Scholar
• Workman P, Burrows F, Neckers L, Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress. Ann NY Acad Sci 2007;1113:202-16
   PubMed Web of Science ®Google Scholar
• Chiosis G, Neckers L. Tumor selectivity of Hsp90 inhibitors: the explanation remains elusive. ACS Chem Biol 2006;1:279-84
   PubMedGoogle Scholar
• Blagg BSJ, Kerr TD. Hsp90 inhibitors: small molecules that transform the Hsp90 protein folding machinery into a catalyst for protein degradation. Med Res Rev 2006;26:310-38
   PubMed Web of Science ®Google Scholar
• Solit DB, Chiosis G. Development and application of Hsp90 inhibitors. Drug Discov Today 2008;13:38-43
   PubMed Web of Science ®Google Scholar
• Chiosis G, Rodina A, Moulick K. Emerging Hsp90 inhibitors: from discovery to clinic. Anticancer Agents Med Chem 2006;6:1-8
   PubMedGoogle Scholar
• Pacey S, Banerji U, Judson I, Hsp90 inhibitors in the clinic. Handb Exp Pharmacol 2006;172:331-58
   Google Scholar
• Peyrat J-F, Messaoudi S, Brion J-D, Inhibitors of the heat shock protein 90: from cancer clinical trials to neurodegenerative diseases. Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2010. Available from: http:/atlasgeneticsoncology.org/Deep/HSP90 inCancer TreatmentID20086.htm
   Google Scholar
• Neckers L. Using natural product inhibitors to validate Hsp90 as a molecular target in cancer. Curr Top Med Chem 2006;6:1163-71
   PubMed Web of Science ®Google Scholar
• Sharp S, Workman P. Inhibitors of the HSP90 molecular chaperone: current status. Adv Cancer Res 2006;95:323-48
   PubMed Web of Science ®Google Scholar
• McDonald E, Workman P, Jones K. Inhibitors of the HSP90 molecular chaperone: attacking the master regulator in cancer. Curr Top Med Chem 2006;6:1091-107
   PubMed Web of Science ®Google Scholar
• Chiosis G. Targeting chaperones in transformed systems–a focus on Hsp90 and cancer. Expert Opin Ther Targets 2006;10:30-57
   Google Scholar
• Sgobba M, Rastelli G. Structure-based and in silico design of Hsp90 inhibitors. ChemMedChem 2009;4:1399-409
   PubMedGoogle Scholar
• Messaoudi S, Peyrat J-F, Brion J-D, Recent advances in Hsp90 inhibitors as antitumor agents. Anticancer Agents Med Chem 2008.8:761-82
   Google Scholar
• Janin YL. ATPase inhibitors of heat-shock protein 90, second season. Drug Discov Today 2010;15:342-53
   PubMed Web of Science ®Google Scholar
• Panaretou B, Prodromou C, Rose SM ATP binding and hydrolysis are essential to the function of the Hsp90 molecular chaperone in vivo. EMBO J 1998;17:4829-36
   PubMed Web of Science ®Google Scholar
• Schulte TW, Neckers LM. ATP binding and hydrolysis are essential to the function of the Hsp90 molecular chaperone in vivo. Cancer Chemother Pharmacol 1998;42:273-9
   PubMed Web of Science ®Google Scholar
• Chiosis G, Huezo H, Rosen NE, 17AAG: low target binding affinity and potent cell activity--finding an explanation. Mol Cancer Ther 2003;2:123-9
   PubMed Web of Science ®Google Scholar
• Supko JG, Hickman RL, Grever MR, Malspeis L. Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother Pharmacol 1995;36:305-15
   PubMed Web of Science ®Google Scholar
• Banerji U, O'Donnell A, Scurr M, Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol 2005;23:4152-61
   PubMed Web of Science ®Google Scholar
• The United States of America represented by the Secretary Department of Health and Human Services. Geldanamycin Derivative and method of treating Cancer using same. WO2002079167, 2002
   Google Scholar
• Solit DB, Ivy SP, Kopil C, Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. Clin Cancer Res 2007;13:1775-82
   PubMed Web of Science ®Google Scholar
• Pacey S, Wilson RH, Walton M, A phase I study of the Heat Shock Protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors. Clin Cancer Res 2011;17:1561-70
   PubMed Web of Science ®Google Scholar
• Ronnen EA, Kondagunta GV, Ishill N, A phase II trial of 17-(Allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma Invest. New Drugs 2006;24:543-6
   Google Scholar
• Kosan Biosciences, Inc. Geldanamycin compounds and method of use. US7259156B2, 2007
   Google Scholar
• Kosan Biosciences, Inc. 11-O-methylgeldanamycin compounds. US6855705B1, 2005
   Google Scholar
• Van Andel Research Institute. Geldamycin and derivatives inhibit cancer invasion and identify novel targets. WO2005095347, 2005
   Google Scholar
• Michigan State University. Geldanamycin derivatives and method of use thereof. WO2007098229, 2007
   Google Scholar
• Guo W, Reigan P, Siegel D, Formation of 17-allylamino-demethoxygeldanamycin (17-AAG) hydroquinone by NAD(P)H:quinone oxidoreductase 1: role of 17-AAG hydroquinone in heat shock protein 90 inhibition. Cancer Res 2005;65:10006-15
   PubMed Web of Science ®Google Scholar
• Guo W, Reigan P, Siegel D, The bioreduction of a series of benzoquinone ansamycins by NAD(P)H:quinone oxidoreductase 1 to more potent heat shock protein 90 inhibitors, the hydroquinone ansamycins. Mol Pharmacol 2006;70:1194-203
   PubMedGoogle Scholar
• Onuoha SC, Mukund SR, Coulstock ET, Mechanistic studies on Hsp90 inhibition by ansamycin derivatives. J Mol Biol 2007;372:287-97
   PubMedGoogle Scholar
• Kelland L, Sharp Y, Rogers PM, DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor ot heat shock protein90. JNCI 1999;91:1940-9
   PubMed Web of Science ®Google Scholar
• Gaspar N, Sharp SY, Pacey S, Acquired resistance to 17-allylamino-17demethoxygeldanamycin (17-AAG, Tanespimycin) in glioblastoma cells. Cancer Res 2009;69:1966-75
   PubMedGoogle Scholar
• Conforma Therapeutics Corp. Hsp90-inhibiting zearalanol compounds and methods of producing and using same. WO2003041643, 2003
   Google Scholar
• Infinity Pharmaceuticals, Inc. Analogs of benzoquinone containing ansamycins for the treatment of cancer. WO2005063714, 2005
   Google Scholar
• Sydor JR, Normant E, Pien CS, Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90. Proc Natl Acad Sci USA 2006;103:17408-13
   PubMed Web of Science ®Google Scholar
• Ge J, Normant E, Porter JR, Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90. J Med Chem 2006;49:4606-15
   PubMed Web of Science ®Google Scholar
• Sydor JR, Normant E, Pien CS, Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90. Proc Natl Acad Sci USA 2006;103:17408-13
   PubMed Web of Science ®Google Scholar
• Roue G, Perez-Galan P, Mozos A, The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosurvival ER chaperone BiP/Grp78. Blood 2011;117:1270-9
   PubMed Web of Science ®Google Scholar
• Kosan Biosciences, Inc. 2-Desmethyl ansamycin compounds. US7241754B2, 2007
   Google Scholar
• Martin JM, Gaisser S, Challis IR, Molecular characterization of macbecin as an Hsp90 inhibitor. J Med Chem 2008;51:2853-7
   PubMedGoogle Scholar
• Legraverend M, Grierson DS. The purines: potent and versatile small molecule inhibitors and modulators of key biological targets. Bioorg Med Chem 2006;14:3987-4006
   PubMed Web of Science ®Google Scholar
• Chiosis G. Discovery and development of purine-scaffold Hsp90 inhibitors. Curr Top Med Chem 2006;6:1183-91
   PubMedGoogle Scholar
• Muranaka K, Sano A, Ichikawa S, Synthesis of Hsp90 inhibitor dimers as potential antitumor agents. Bioorg Med Chem 2008;16:5862-70
   PubMedGoogle Scholar
• Chiosis G, Timaul MN, Lucas B, A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells. Chem Biol 2001;8:289-99
   PubMed Web of Science ®Google Scholar
• Sloan Kettering Institute for Cancer Research. Small molecule compositions for binding to Hsp90. WO200236075, 2002
   Google Scholar
• Chiosis G, Lucas B, Shtil A, Development of a purine-scaffold novel class of Hsp90 binders that inhibit the proliferation of cancer cells and induce the degradation of Her2 tyrosine kinase. Bioorg Med Chem 2002;10:3555-64
   PubMed Web of Science ®Google Scholar
• Llauger L, He H, Kim J, Evaluation of 8-arylsulfanyl, 8-arylsulfoxyl, and 8-arylsulfonyl adenine derivatives as inhibitors of the heat shock protein 90. J Med Chem 2005;48:2892-905
   PubMed Web of Science ®Google Scholar
• Zhang L, Fan J, Vu K, 7'-substituted benzothiazolothio- and pyridinothiazolothio-purines as potent heat shock protein 90 inhibitors. J Med Chem 2006;49:5352-62
   PubMed Web of Science ®Google Scholar
• Biamonte MA, Shi J, Hong K, Orally active purine-based inhibitors of the heat shock protein 90. J Med Chem 2006;49:817-28
   PubMed Web of Science ®Google Scholar
• Sloan Kettering Institute for Cancer Research. Small molecule compositions for binding to Hsp90. Small-molecule Hsp90 inhibitors. WO2006084030, 2006
   Google Scholar
• Sloan Kettering Institute for Cancer Research. Treatment of neurodegenerative diseases through inhibition of Hsp90. WO2008005937, 2008
   Google Scholar
• Conforma Therapeutics Corp. Orally active purine-based inhibitors of heat shock protein 90. WO2007075572, 2007
   Google Scholar
• Immormino RM, Kang Y, Chiosis G, Gewirth DT. Structural and quantum chemical studies of 8-aryl-sulfanyl adenine class Hsp90 inhibitors. J Med Chem 2006;49:4953-60
   PubMed Web of Science ®Google Scholar
• Myriad Genetics, Inc. Therapeutics compounds and their use in treating diseases and disorders. WO2007134298, 2007
   Google Scholar
• Myriad Genetics, Inc. Therapeutics compounds and their use in cancer. WO2009065035, 2009
   Google Scholar
• Chroma Terapeutics Ltd. Adenine derivatives as inhibitors of Hsp90 for the treatment of cancer. WO2008056120, 2008
   Google Scholar
• Chroma Terapeutics Ltd. Purine derivatives suitable for the treatment of cancer, autoimmune and inflammatory diseases. WO2009136144, 2009
   Google Scholar
• Wyeth. Sulfamoyl-containing derivatives and uses thereof. WO2008049105, 2008
   Google Scholar
• Curis, Inc. Hsp90 inhibitors containing a zinc binding moiety. WO008115262, 2008
   Google Scholar
• Dymock B, Barril X, Beswick M, Adenine derived inhibitors of the molecular chaperone Hsp90sSAR explained through multiple X-ray structures. Bioorg Med Chem Lett 2004;14:325-8
   PubMed Web of Science ®Google Scholar
• Kasibhatla SR, Hong K, Biamonte MA, Rationally designed high-affinity 2-amino-6-halopurine heat shock protein 90 inhibitors that exhibit potent antitumor activity. J Med Chem 2007;50:2767-78
   PubMed Web of Science ®Google Scholar
• Conforma Therapeutics Corp. Anti-tumor methods using multi drug resistance independant synthetic Hsp90 inhibitors. WO2007035963, 2007
   Google Scholar
• Elfiky A, Saif MW, Beeram M, BIIB021, an oral, synthetic non-ansamycin Hsp90 inhibitor: Phase I experience. J Clin Oncol 2008;26(Suppl); abstract 2503
   Google Scholar
• Lundgren K, Zhang H, Brekken J, BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90. J Mol Cancer Ther 2009;4:921-9
   Google Scholar
• Avantis Pharma S. A. Use of purine derivatives as Hsp90 protein inhibitors and for treatment of cancer. WO2006075095, 2006
   Google Scholar
• Merck Patent GMBH. Adenine derivatives. WO2007017069, 2007
   Google Scholar
• Vernalis (R & D) Ltd. Purine compounds as Hsp90 protein inhibitors for the treatment of cancer. WO2007034185, 2007
   Google Scholar
• Vernalis (R & D) Ltd. 1H-pyrrolo[2,3-B] pyridine derivatives useful as Hsp90 inhibitors. WO2008025947, 2008
   Google Scholar
• Conforma Therapeutics Corp. Novel heterocyclic compounds as Hsp90 inhibitors. WO2005028434, 2005
   Google Scholar
• Conforma Therapeutics Corp. Alkynyl pyrrolopyrimidines and related analogs as Hsp90 inhibitors. WO2006105372, 2006
   Google Scholar
• Chroma Terapeutics Ltd. Pyrrolo[2,3-D] pyrimidines as inhibitors of Hsp90. WO2010043867, 2010
   Google Scholar
• Chroma Terapeutics Ltd. Inhibitors of Hsp90. WO2010043865, 2010.
   Google Scholar
• Vernalis (R & D) Ltd. Pyrrolopyrimidine derivatives used as Hsp90 inhibitors. WO2007104944, 2007
   Google Scholar
• Vernalis (R & D) Ltd. Pyrrolopyrimidine derivatives having Hsp90 inhibitory activity. WO2009030871, 2009
   Google Scholar
• Biogen Idec Ma, Inc. Certain substituted pyrimidines, pharmaceutical compositions thereof, and methods for their use. WO2010117425, 2010
   Google Scholar
• Poniard Pharmaceuticals, Inc. Bioactive compounds for treatment of cancer and neurodegenerative diseases. WO2009139834, 2009
   Google Scholar
• Pfizer, Inc. 2-amino-5,7-dihydro-6H-pyrrolo [3,4-D] pyrimidine derivatives as Hsp90 inhibitors for treating cancer. WO2008096218, 2008
   Google Scholar
• Pfizer, Inc. 2-amino pyrimidine compounds as potent Hsp-90 inhibitors. WO2010018481, 2010
   Google Scholar
• Vernalis (R & D) Ltd. Pyrimidothiophene compounds having Hsp90 activity. WO2006079789, 2006
   Google Scholar
• Vernalis (R & D) Ltd. Pyrimidothiophene compounds for use as Hsp90 inhibitors. WO2006090094, 2006
   Google Scholar
• Vernalis (Cambridge) Ltd. Pyrimidothiophene compounds. WO2006008503, 2006
   Google Scholar
• Brough PA, Barril X, Borgognoni J, Combining hit identification strategies: fragment-based and in silico approaches to orally active 2-aminothieno[2,3-d]pyrimidine inhibitors of the Hsp90 molecular chaperone. J Med Chem 2009;52:4794-809
   PubMed Web of Science ®Google Scholar
• Pfizer, Inc. 2-amino pyrimidine compounds. WO2008059368, 2008
   Google Scholar
• Daiichi Sankyo Co., Ltd. Tricyclic pyrazolopyrimidine derivative. WO2010098344, 2010
   Google Scholar
• Novartis AG. 2-amino-7,8-dihydro-6H-pyrido[4,3-D]pyrimidi-5-ones. WO2007041362, 2007
   Google Scholar
• Novartis AG. Hsp90 inhibitors for therapeutic treatment. WO2010060940, 2010
   Google Scholar
• Takeda Pharmaceutical Co., Ltd. Oxim derivatives as Hsp90 inhibitors. WO2009097578, 2009
   Google Scholar
• Serenex, Inc. Isoquinoline, quinazoline and phthalazine derivatives. WO2008024977, 2008
   Google Scholar
• Merck Patent GMBH. Quinazolinamide derivatives. WO2010066324, 2010
   Google Scholar
• Merck Patent GMBH. Quinazolinamide derivatives. WO2009010139, 2009
   Google Scholar
• Novartis Vaccines and Diagnostics, Inc. 2-amino-quinazolin-5-ones as Hsp90 inhibitors useful in treating proliferation diseases. WO2006113498, 2006
   Google Scholar
• Dac Srl. Quinazolin oxime derivatives as Hsp90 inhibitors. WO2008142720, 2008
   Google Scholar
• Barke JJ, Barker O, Boggio R, Fragment-based identification of Hsp90 inhibitors. ChemMedChem 2009;4:963-6
   PubMedGoogle Scholar
• Astrazeneca UK Ltd. 5,6,7,8-tetrahydropteridine derivatives as Hsp90 inhibitors. WO2008093075, 2008
   Google Scholar
• Merck Patent GMBH. Thienopyridines. WO2006125531, 2006
   Google Scholar
• Merck Patent GMBH. Thienopyridine derivatives and use thereof as Hsp90 modulators. WO2006092202, 2006
   Google Scholar
• Curis, Inc. Fused amino pyridine as Hsp90 inhibitors. WO2008115719, 2008
   Google Scholar
• Bao R, Lai C-J, Qu H, CUDC-305, a novel synthetic HSP90 inhibitor with unique pharmacologic properties for cancer therapy. Clin Cancer Res 2009;15:4046-57
   PubMed Web of Science ®Google Scholar
• McDonald E, Jones K, Brough PA, Discovery and development of pyrazole-scaffold Hsp90 inhibitors. Curr Top Med Chem 2006;6:1193-203
   PubMed Web of Science ®Google Scholar
• Rowlands MG, Newbatt YM, Prodromou C, High-throughput screening assay for inhibitors of heat-shock protein 90 ATPase activity. Anal Biochem 2004;327:176-83
   PubMed Web of Science ®Google Scholar
• Cheung KM, Matthews TP, James K, The identification, synthesis, protein crystal structure and in vitro biochemical evaluation of a new 3,4-diarylpyrazole class of Hsp90 inhibitors. Bioorg Med Chem Lett 2005;15:3338-43
   PubMed Web of Science ®Google Scholar
• Sharp SY, Boxall K, Rowlands M, In vitro biological characterization of a novel, synthetic diaryl pyrazole resorcinol class of heat shock protein 90 inhibitors. Cancer Res 2007;67:2206-16
   PubMed Web of Science ®Google Scholar
• Dymock BW, Barril X, Brough PA, Novel, potent small-molecule inhibitors of the molecular chaperone Hsp90 discovered through structure-based design. J Med Chem 2005;48:4212-15
   PubMed Web of Science ®Google Scholar
• Vernalis (Cambridge) Ltd. 3-(2-hydroxy-phenyl)-1H-pyrazole-4-carboxylic acid amide derivatives as Hsp90 inhibitors for the treatment of cancer. WO2004050087, 2004
   Google Scholar
• Vernalis (Cambridge) Ltd. Pyrazole compounds as Hsp90 inhibitors for the treatment of cancer. WO2004096212, 2004
   Google Scholar
• Brough PA, Barril X, Beswick M, 3-(5-Chloro-2,4-dihydroxyphenyl)-pyrazole-4-carboxamides as inhibitors of the Hsp90 molecular chaperone. Bioorg Med Chem Lett 2005;15:5197-201
   PubMed Web of Science ®Google Scholar
• Brough PA, Aherne W, Barril X, 4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer. J Med Chem 2008;51:196-218
   PubMed Web of Science ®Google Scholar
• Kreusch A, Han S, Brinker A, Crystal structures of human HSP90 alpha-complexed with dihydroxyphenylpyrazoles. Bioorg Med Chem Lett 2005;15:1475-8
   PubMed Web of Science ®Google Scholar
• Merck Patent GMBH. 1.5-diphenylpyrazoles. WO2006018082, 2006
   Google Scholar
• Merck Patent GMBH. 3-(2-hydroxyphenyl) pyrazoles and their use as Hsp90 inhibitors. WO2006039977, 2006
   Google Scholar
• Synta Pharmaceuticals Corp. Pyrazole compounds that modulate Hsp90 activity. WO2007021966, 2007
   Google Scholar
• Chandarlapaty S, Sawai A, Ye Q, SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers. Clin Cancer Res 2008;14:24048
   Google Scholar
• Serenex, Inc. Isoquinoline, quinazoline and phthalazine derivatives. WO2008024977, 2008
   Google Scholar
• Vernalis (Cambridge) Ltd. Isoxazole compounds as inhibitors of heat shock proteins. WO2004072051, 2004
   Google Scholar
• Sharp SY, Prodromou C, Boxall K, Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues. Mol Cancer Ther 2007;6:1198-211
   PubMed Web of Science ®Google Scholar
• Eccles SA, Massey A, Raynaud F, I. NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res 2008;68:2850-60
   PubMed Web of Science ®Google Scholar
• Novartis AG. Acid addition salts, hydrates and polymorphs of (-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide and formulations comprising these forms. WO2008104595, 2008
   Google Scholar
• Curis, Inc. Hsp90 inhibitors containing a zinc boinding moiety. WO2009036012, 2009
   Google Scholar
• Nerviano Medical Sciences S.R.L. Bicyclic pyrazole and isoxazole derivatives as antitumor and antineurodegenerative agents. WO2010060854, 2010
   Google Scholar
• Nerviano Medical Sciences S.R.L. Resorcinol derivatives as Hsp90 ihnibitors. WO2010121963, 2010
   Google Scholar
• Sigma-Tau Research Switzerland. 5-phenyl-isoxazole-3-carboxamides modulating Hsp90 with antitumoral activities. WO2010000748, 2010
   Google Scholar
• Merck Patent GMBH. Hsp90-inhibiting triazole derivatives. WO2006087077, 2006
   Google Scholar
• Merck Patent GMBH. triazole derivatives II. WO2007134678, 2007
   Google Scholar
• Synta Pharmaceuticals Corp. Triazole compounds that modulate Hsp90 activity. WO2007139967, 2007
   Google Scholar
• Synta Pharmaceuticals Corp. Triazole compounds that modulate Hsp90 activity. WO2007094819, 2007
   Google Scholar
• Synta Pharmaceuticals Corp. Triazole compounds that modulate Hsp90 activity. WO2007139968, 2007
   Google Scholar
• Nippon Kayaku Kabushiki kaisha. Novel Hsp90 inhibitors. WO2006095783, 2006
   Google Scholar
• Merck Patent GMBH. Hsp90-inhibiting triazole derivatives. WO2006087077, 2006
   Google Scholar
• Synta Pharmaceuticals Corp. Triazole compounds that modulate Hsp90 activity. WO2006055760, 2006
   Google Scholar
• Synta Pharmaceuticals Corp. Tricyclic triazole compounds that modulate Hsp90 activity. WO2009139916, 2009
   Google Scholar
• Synta Pharmaceutics Corp. Method for treating non-Hodgkin's lymphoma. WO2007140002, 2007
   Google Scholar
• Synta Pharmaceutics Corp. Triazole compounds that modulate Hsp90 activity. WO20007139955, 2000
   Google Scholar
• Synta Pharmaceutics Corp. Method for treating proliferative disorders associated with protooncogene products. WO2007139951, 2007
   Google Scholar
• Synta Pharmaceutics Corp. Compounds that modulate Hsp90 activity and methods for identifying same. WO2007139960, 2007
   Google Scholar
• Synta Pharmaceutics Corp. Triazole compounds that modulate Hsp90 activity. WO2008021364, 2008
   Google Scholar
• Synta Pharmaceutics Corp. Method for treating infections. WO2008051416, 2008
   Google Scholar
• Synta Pharmaceutics Corp. Triazole compounds that modulate Hsp90 activity. WO2008097640, 2008
   Google Scholar
• Synta Pharmaceutics Corp. Triazole compounds that modulate Hsp90 activity. WO2008103353, 2008
   Google Scholar
• Synta Pharmaceutics Corp. Method for inhibiting topoisomerase II. WO2008112199, 2008
   Google Scholar
• Synta Pharmaceutics Corp. Method for treating proliferative disorders associated with mutations in C-Met. WO2008153730, 2008
   Google Scholar
• Synta Pharmaceutics Corp. Triazole compounds that modulate Hsp90 activity. WO2009023211, 2009
   Google Scholar
• Synta Pharmaceutics Corp. Triazole compounds that modulate Hsp90 activity. WO2009075890, 2009
   Google Scholar
• Synta Pharmaceutics Corp. Triazole compounds that modulate Hsp90 activity. WO2010017545, 2010
   Google Scholar
• Synta Pharmaceutics Corp. Triazole compounds that modulate Hsp90 activity. WO2010017479, 2010
   Google Scholar
• Cristax Pharmaceuticals, S. L. New compounds as Hsp90 inhibitors. WO2009007399, 2009
   Google Scholar
• Synta Pharmaceutics Corp. Method for inhibiting topoisomerase II. WO2008112199, 2008
   Google Scholar
• Feldman RI, Mintzer B, Zhu D, Potent triazolothione inhibitor of heat-shock protein-90. Chem Biol Drug Des 2009;74:43-50
   PubMed Web of Science ®Google Scholar
• Available from: http://www.syntapharma.com/PrdHsp90.aspx
   Google Scholar
• Available from: http://clinicaltrials.gov
   Google Scholar
• Synta Pharmaceutics Corp. Imidazole compounds that modulate Hsp90 activity. WO2007021877, 2007
   Google Scholar
• Topotarget A/S. 4-substituted-6-isopropyl-benzene-1,3-diol compounds and their use. WO2009066060, 2009
   Google Scholar
• Synta Pharmaceutics Corp. Pyrrole compounds that modulate Hsp90 activity. WO2009148599, 2009
   Google Scholar
• Arqule, Inc. Substituted tetrazole compounds and uses thereof. WO2009049305, 2009
   Google Scholar
• Synta Pharmaceutics Corp. Compounds that modulate Hsp90 activity. WO2008118391, 2008
   Google Scholar
• Chugai Seiyaku Kabushiki Kaisha. Hsp90 inhibitors. WO2007138994, 2007
   Google Scholar
• Biotechnologijos Institutas. 5-aryl-4-(5-substituted 2,4-Dihydroxyphenyl)-1,2,3-thiadiazoles as inhibitors of Hsp90 chaperone and the intermediates for production thereof. WO2009134110, 2009
   Google Scholar
• Novartis AG. Inhibitors of Hsp90. WO2006010595, 2006
   Google Scholar
• Novartis AG. Inhibitors of Hsp90. WO2006010594, 2006
   Google Scholar
• Astex Therapeutics Ltd. Hydroxybenzamide derivatives and their use as inhibitors. WO2006109085, 2006
   Google Scholar
• Astex Therapeutics Ltd. Hydroxybenzamide derivatives and their use as inhibitors. WO2006109075, 2006
   Google Scholar
• Synta Pharmaceutics Corp. Hydrozamide compounds that modulate Hsp90 activity. WO2009158026, 2009
   Google Scholar
• Astex Therapeutics Ltd. Pharmaceutical compounds. WO2008044027, 2008
   Google Scholar
• Astex Therapeutics Ltd. Pharmaceutical combinations. WO2008044029, 2008
   Google Scholar
• Astex Therapeutics Ltd. Pharmaceutical combinations. WO2008044041, 2008
   Google Scholar
• Astex Therapeutics Ltd. Pharmaceutical combinations. WO2008044045, 2008
   Google Scholar
• Astex Therapeutics Ltd. Pharmaceutical compounds. WO2008044054, 2008
   Google Scholar
• Pfizer Products, Inc. Amide resorcinol compounds. WO2008053319, 2008
   Google Scholar
• Merck Patent GMBH. 1,3-dihydroisoindole derivatives. WO2009030316, 2009
   Google Scholar
• Merck Patent GMBH. Quinazolinamide derivatives. WO2009010139, 2009
   Google Scholar
• Astex Therapeutics Ltd. Hydrobenzamide derivatives as inhibitors of Hsp90. WO2008044034, 2008
   Google Scholar
• Astex Therapeutics Ltd. Pharmaceutical compounds. WO2009125230, 2009
   Google Scholar
• Sanofi-Aventis. Novel derivatives of pyrroloindole inhibitors of Hsp90, compositions containing same, and use thereof. WO2009153516, 2009
   Google Scholar
• Sanofi-Aventis. Novel Hsp90 inhibitory carabozole derivatives, compositions containing same, and use thereof. WO2009122034, 2009
   Google Scholar
• Avantis Pharma S. A. Novel isoindole derivatives, compositions containing same, preparation thereof and pharmaceutical uses thereof in particular as ihnibitors of chaperone protein Hsp90 activities. WO2006108948, 2006
   Google Scholar
• Curis, Inc. Tetrahydroindole and tetrahydroindazole as Hsp90 inhibitors containing a zinc binding moiety. WO2009114470, 2009
   Google Scholar
• Serenex, Inc. Benzene, pyridine, and pyridazine derivatives. WO2008024970, 2008
   Google Scholar
• Serenex, Inc. Dihydropyridazine, tetrahydropyridine, chromanone, and dihydronaphthalenone derivatives as heat shock protein 90 inhibitors. WO2008024961, 2008
   Google Scholar
• Serenex, Inc. Benzene, pyridine, and pyridazine derivatives. WO2008024978, 2008
   Google Scholar
• Serenex, Inc. Benzene, pyridine, and pyridazine derivatives. WO2008024963, 2008
   Google Scholar
• Janin YL. ATPase inhibitors of heat-shock protein 90, second season. Drug Discov Today 2010;15:342-53
   Google Scholar
• University of Kansas. Therapeutic methods with withaferin A and analogs. WO2010053655, 2010
   Google Scholar
• Yu Y, Hamza A, Zhang T, Whithaferin A targets heat shock protein 90 in pancreatic cancer cells. Biochem Pharmacol 2010;79:542-51
   PubMed Web of Science ®Google Scholar
• Emory University. Heat shock protein 90 inhibitors, methods of preparing same, and methods for their use. WO2010042500, 2010
   Google Scholar
• Emory University. Aminoquinoline derived heat shock protein 90 inhibitors, methods of preparing same, and methods for their use. WO2010042489, 2010
   Google Scholar
• Sanofi-Avantis. Novel herbimycin a analogue derivatives, compositions containing same and use thereof. WO2009004146, 2009
   Google Scholar
• Ex-elixis, Inc. Tropane compounds. WO2009055077, 2009
   Google Scholar
• Soga S, Shiotsu Y, Akinaga S, Development of radicicol analogues. Curr Cancer Drug Targets 2003;3:359-69
   PubMed Web of Science ®Google Scholar
• Yamamoto K, Garbaccio RM, Stachel SJ. Total synthesis as a resource in the discovery of potentially valuable antitumor agents: cycloproparadicicol. Angew Chem Int Ed Engl 2003;42:1280-4
   PubMed Web of Science ®Google Scholar
• Kyowa Hakko Kogyo Co., Ltd. Radicicol derivatives. WO199955689, 1999
   Google Scholar
• Moulin E, Zoete V, Barluenga S, Design, synthesis, and biological evaluation of HSP90 inhibitors based on conformational analysis of radicicol and its analogues. J Am Chem Soc 2005;127:6999-7004
   PubMed Web of Science ®Google Scholar
• Shen G, Blagg BS. Radester, a novel inhibitor of the Hsp90 protein folding machinery. Org Lett 2005;7:2157-60
   PubMedGoogle Scholar
• Clevenger RC, Blagg BS. Design, synthesis, and evaluation of a radicicol and geldanamycin chimera, radamide. Org Lett 2004;6:4459-62
   PubMedGoogle Scholar
• Wang M, Shen G, Blagg BS. Radanamycin, a macrocyclic chimera of radicicol and geldanamycin. Bioorg Med Chem Lett 2006;16:2459-62
   PubMedGoogle Scholar
• Nexgenix Pharmaceuticals. Treatment of neurofibromatoses with Hsp90 ihnibitors. WO2007143630, 2007
   Google Scholar
• Nexgenix Pharmaceuticals. Treatment of neurofibromatoses with radicicol and its derivatives. WO2008150302, 2008
   Google Scholar
• Wissinger N, Barluenga S, Karplus M. WO2008021213, 2008
   Google Scholar
• Universite de Strasbourg. Synthesis of resorcylic acid lactones useful as therapeutic agents. WO2009091921, 2009
   Google Scholar
• Nexgenix Pharmaceuticals/Universite de Strasbourg. Macrocyclic prodrug compounds useful as therapeutics. WO2009105755, 2009
   Google Scholar
• University of Kansas. Novobiocin analogues having modified sugar moieties. WO2010096650, 2010
   Google Scholar
• Mimnaugh EG, Chavany C, Neckers L. Polyubiquitination and proteasomal degradation of the p185c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin. J Biol Chem 1996;271:22796-801
   PubMed Web of Science ®Google Scholar
• Biamonte MA, Van de Water R, Arndt JW, Heat Shock Protein 90: inhibitors in clinical trials. J Med Chem 2010;53:3-17
   PubMed Web of Science ®Google Scholar
• Zhang L, Hamza A, Cao X, A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells. Mol Cancer Ther 2008;7:162-70
   PubMed Web of Science ®Google Scholar
• Pearl LH, Prodromou C. Structure and mechanism of the Hsp90 molecular chaperone: an open and shut case for treatment. Biochem J 2008;410:439-53
   PubMed Web of Science ®Google Scholar
• Plescia J, Salz W, Xia F, Rational design of shepherdin, a novel anticancer agent. Cancer Cell 2005;7:457-68
   PubMed Web of Science ®Google Scholar
• Soldano KL, Jivan A, Nicchitta A, Structure of the N-terminal domain of GRP94: basis for ligand specificity and regulation. J Biol Chem 2003;48:48330-8
   Google Scholar
• Wandinger SK, Suhre MH, Wegele H, The phosphatase Ppt1 is a dedicated regulator of the molecular chaperone Hsp90. EMBO J 2006;25:367-76
   PubMed Web of Science ®Google Scholar
• Marcu MG, Schulte TW, Neckers L. Novobiocin and related coumarins and depletion of Heat Shock Protein 90-dependent signaling proteins. J Natl Cancer Inst 2000;92:242-8
   PubMed Web of Science ®Google Scholar